MRSN

1.39

0.71% -0.01

Handel nachbörslich: 1.45 0.06 +4.32%

Mersana Therapeutics Inc (MRSN)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$1.40

Offen:

$1.42

24-Stunden-Volumen:

2.63M

Relative Volume:

2.20

Marktkapitalisierung:

$171.71M

Einnahmen:

$36.86M

Nettoeinkommen (Verlust:

$-171.67M

KGV:

-0.9267

EPS:

-1.5

Netto-Cashflow:

$-171.05M

1W Leistung:

-7.33%

1M Leistung:

-41.35%

6M Leistung:

-24.46%

1J Leistung:

-35.65%

1-Tages-Spanne:

$1.37

$1.455

1-Wochen-Bereich:

$1.35

$1.515

52-Wochen-Spanne:

$1.22

$6.2801

Mersana Therapeutics Inc Stock (MRSN) Company Profile

Firmenname

Mersana Therapeutics Inc

Sektor

Healthcare (1174)

Branche

Biotechnology (669)

Telefon

617-498-0020

Adresse

840 MEMORIAL DRIVE, CAMBRIDGE

Mitarbeiter

123

Twitter

@MersanaADC

Nächster Verdiensttermin

2024-11-05

Neueste SEC-Einreichungen

MRSN's Discussions on Twitter

Vergleichen Sie MRSN mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
MRSN Mersana Therapeutics Inc	1.39	171.71M	36.86M	-171.67M	-171.05M	-1.50
VRTX Vertex Pharmaceuticals Inc	407.11	104.84B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	718.15	78.92B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	621.29	37.15B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	234.28	30.22B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	115.79	27.76B	3.30B	-501.07M	1.03B	-2.1146

Mersana Therapeutics Inc Stock (MRSN) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-11-15	Fortgesetzt	Citigroup	Buy
2024-03-19	Hochstufung	JP Morgan	Underweight → Neutral
2024-02-29	Hochstufung	BTIG Research	Neutral → Buy
2024-02-29	Hochstufung	Guggenheim	Neutral → Buy
2024-02-29	Hochstufung	Wedbush	Neutral → Outperform
2023-12-04	Hochstufung	Citigroup	Neutral → Buy
2023-07-28	Herabstufung	Robert W. Baird	Outperform → Neutral
2023-07-27	Herabstufung	BTIG Research	Buy → Neutral
2023-07-27	Herabstufung	Citigroup	Buy → Neutral
2023-07-27	Herabstufung	Guggenheim	Buy → Neutral
2023-07-27	Herabstufung	JP Morgan	Neutral → Underweight
2023-07-27	Herabstufung	Truist	Buy → Hold
2023-07-27	Herabstufung	Wedbush	Outperform → Neutral
2023-06-16	Herabstufung	JP Morgan	Overweight → Neutral
2023-06-15	Eingeleitet	Guggenheim	Buy
2023-03-16	Hochstufung	JP Morgan	Neutral → Overweight
2023-01-20	Eingeleitet	Citigroup	Buy
2022-11-21	Eingeleitet	Truist	Buy
2021-10-15	Fortgesetzt	BTIG Research	Buy
2021-08-30	Eingeleitet	H.C. Wainwright	Buy
2021-03-31	Eingeleitet	Credit Suisse	Neutral
2020-12-03	Eingeleitet	Stifel	Buy
2020-09-29	Fortgesetzt	JP Morgan	Neutral
2020-04-29	Eingeleitet	BTIG Research	Buy
2020-01-21	Bestätigt	H.C. Wainwright	Buy
2019-03-11	Herabstufung	JP Morgan	Neutral → Underweight
2018-11-14	Hochstufung	Leerink Partners	Mkt Perform → Outperform
2018-05-08	Eingeleitet	Robert W. Baird	Outperform
2018-03-19	Herabstufung	JP Morgan	Overweight → Neutral

Alle ansehen

Mersana Therapeutics Inc Aktie (MRSN) Neueste Nachrichten

Dec 31, 2024

Barclays PLC Increases Stock Position in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World

Dec 31, 2024

Dec 30, 2024

State Street Corp Has $5.15 Million Holdings in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World

Dec 30, 2024

Dec 28, 2024

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Dec 28, 2024

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World

Dec 28, 2024

Dec 19, 2024

Fmr LLC Acquires 32,332 Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World

Dec 19, 2024

Mersana Therapeutics: We're About To Find Out If Their ADC Platform Is More Tolerable - Seeking Alpha

Dec 19, 2024

Dec 15, 2024

BNP Paribas Financial Markets Sells 98,881 Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World

Dec 15, 2024

Dec 13, 2024

XTX Topco Ltd Acquires 225,823 Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN) - MarketBeat

Dec 13, 2024

Dec 08, 2024

Jacobs Levy Equity Management Inc. Has $1.88 Million Stock Position in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - MarketBeat

Dec 08, 2024

Dec 06, 2024

Verition Fund Management LLC Increases Stock Holdings in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - MarketBeat

Dec 06, 2024

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Shares Sold by Atom Investors LP - MarketBeat

Dec 06, 2024

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Receives $6.00 Consensus Target Price from Analysts - Defense World

Dec 06, 2024

Dec 03, 2024

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat

Dec 03, 2024

Dec 01, 2024

Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Price Is Right But Growth Is Lacking After Shares Rocket 25% - Simply Wall St

Dec 01, 2024

Nov 28, 2024

Acuta Capital Partners LLC Sells 463,000 Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN) - MarketBeat

Nov 28, 2024

Nov 24, 2024

Mersana Therapeutics (FRA:0M4) 3-Year EBITDA Growth Rate : -0.50% (As of Sep. 2024) - GuruFocus.com

Nov 24, 2024

Mersana Therapeutics (FRA:0M4) Future 3-5Y EPS without NRI Growth Rate : 17.91 (As of Nov. 24, 2024) - GuruFocus.com

Nov 24, 2024

Mersana Therapeutics (FRA:0M4) Forward Dividend Yield % : 0.00% (As of Nov. 24, 2024) - GuruFocus.com

Nov 24, 2024

Nov 23, 2024